World Health Organization Department of Chronic Diseases and Health Promotion Global Initiative For Treatment of major chronic diseases Shanthi Mendis.

Slides:



Advertisements
Similar presentations
Things we knew, things we did… Things we have learnt, things we should do LIPID MANAGEMENT IN PRIMARY CARE: HOW WELL DO WE DO? Dr. Carlos Brotons Research.
Advertisements

UN High-Level Meeting puts NCDs on the map. Presentation 4 chapters 1. Who are/is behind is ? (stakeholders) – who is missing 2. What is at stake ? –
Ten years of the CHD NSF Professor Roger Boyle CBE National Director for Heart Disease and Stroke Department of Health.
The Burden of Obesity in North Carolina Obesity-Related Chronic Disease.
1 What do we know about access to chronic disease medicines ? Dr Shanthi Mendis Coordinator Chronic Diseases Prevention and Management Department of Chronic.
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Cancer Control in the EMR Dr. Haifa Madi Director, Health Protection and Promotion WHO/EMRO.
Architecture & The Nations Health: Design Matters ASLA Conference Washington, DC May 7, 2003 Jamie Bussel, MPH.
GARD Global Alliance against Chronic Respiratory Diseases WHO J Bousquet, R Dahl, N Khaltaev, HJ Bekedam.
PRIMIS Third National Conference Tuesday 1 April 2003 Birmingham HIP for CHD Jane Matthews Practice Nurse Dr. Dai Evans PRIMIS Regional Clinical Adviser.
Stroke Management in Developing Countries Junaid A. Razzak MD PhD FACEP Chief, Section of Emergency Medicine Aga Khan University Karachi, Pakistan.
Monitoring and measuring UHC. 2 Policy and planning Monitoring and Measuring UHC Key Messages Equity is fundamental to UHC – all people get services they.
Nurse Led Clinics Opportunity for nurses to make a difference Wilma Scholte op Reimer, RN, PhD Amsterdam School of Health Professions Academic Medical.
Review of Health Inequalities at the local level Maggie Rae Head of Health Inequalities & Head of Local Delivery 11 May 2006.
What can Actavis contribute for the sustainability in the health care system?
The Almanac of Chronic Disease 2008 Edition. 2 Table of Contents I.The Human Cost Today II.The Economic Cost Today III.The Cost Tomorrow IV.Opportunity.
Wellness S Y M P O S I U M Darwin R. Labarthe, MD, MPH, PhD Director, Division for Heart Disease and Stroke Prevention.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
1 Integration of Noncommunicable Diseases into PHC in low-resource settings Lessons learned Dr Shanthi Mendis Chronic Disease Prevention and Management.
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Gojka Roglic THE GLOBAL BURDEN OF DIABETES AND.
Course 17: Neglected Tropical Diseases & NCDs 9 th GA of IAPB Hyderabad; 19 th September 2012 NCDs & Eye Health Converging interests and opportunities.
Non-communicable diseases David Redfern
Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
World Health Organisation Internship
WHO Technical Briefing Seminar on Essential Medicines & Health Products, October 2013 Noncommunicable Diseases –Action Plan Dr Shanthi Mendis Director,
Public Health. CVDDiabetesCancer Antibiotic Resistance.
EXAM 1.A normal adult should have their BP checked at least how often? 2.What level of CVD risk over 10 years is considered high risk for primary prevention?
4 th SIDS Meeting, Sao Tome & Principe April |1 | NCDs in the context of the revised Health Promotion Strategy.
Global Alliance against Chronic Respiratory Diseases GARD/NCD Action Plan & 2011 UN Summit on NCDs Niels H. Chavannes MD PhD Associate.
Owen Smith – World Bank Washington DC – February 1 st, 2011 Health care financing in Georgia.
Innovations in Management of Cardiovascular Disease for Global Health
Reporter Shiu Ruei-Shiang Director of Adult and Elderly Health Bureau of Health Promotion.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Polypill x Aspirin Project Groups 3 and 4
Source: WHO Global Burden of Disease Report Update 2004, Geneva 2008 Global Burden of Disease: chronic NCD responsible for high rates of premature mortality.
The Burden of Chronic Diseases in the Developing World Stephen J. Spann, M.D., M.B.A. Professor and Chairman Department of Family and Community Medicine.
Diabetes: 0–44 years Ranked comorbidity combinations Source: ABS Australian Health Survey 2011–12 (National Health Survey component) For people aged 0–44,
EMPOWER, EQUIP, ADVOCATE GLOBAL HEALTH & WASH The Sphere Project Humanitarian Charter and Minimum Standards in Humanitarian Response Standards for addressing.
Klaus F. Rabe MD, PhD and the Challenges of Chronic Respiratory Disease...
Non-communicable diseases (NCDs) include:
Reducing the NCD morbidity and mortality
Cardiovascular Disease Expert Consultation (PAHO)
DR GHULAM NABI KAZI WHO Country Office Pakistan
Implementing a National NCD Program Population Based and High Risk Approaches to Prevention and Control of NCDs/CVD Dr Shanthi Mendis MBBS MD FRCP.
World Health Organization
Epidemiology, Burden and Primary Prevention of Cardiovascular Disease Dr Shanthi Mendis MBBS MD FRCP FACC Coordinator Chronic Disease Prevention.
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
How does teamwork improve value. Dr Nils E
NCD in Uruguay Ministry of Health Non-communicable Diseases Program
GARD/NCD Action Plan & 2011 UN Summit on NCDs
The IDEAL Study Reference
Non-communicable diseases (NCDs) include:
Design & create your innovation
Design & create your innovation
Design & create your innovation
عوامل اجتماعی موثر بر سلامت
Design & create your innovation
Design & create your innovation
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Design & create your innovation
Design & create your innovation
Design & create your innovation
Design & create your innovation
Design & create your innovation
Design & create your innovation
Dr Timothy Armstrong Coordinator
Design & create your innovation
FIELD: Primary outcome
Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.
Presentation transcript:

World Health Organization Department of Chronic Diseases and Health Promotion Global Initiative For Treatment of major chronic diseases Shanthi Mendis MD FRCP FACC Coordinator Cardiovascular Diseases

World Health Organization Department of Chronic Diseases and Health Promotion Global Initiative For Treatment of major chronic diseases Rationale Objectives Processes / activities Expected outcomes

World Health Organization Department of Chronic Diseases and Health Promotion Rationale Mortality CVD 16.7 million Diabetes 0.98 million CRD 3.7 million Cancer 7.0 million 42% of NCD burden CVD Diabetes CRD Cancer

World Health Organization Department of Chronic Diseases and Health Promotion Number of Cardiovascular Deaths Projected to 2020 Millions

World Health Organization Department of Chronic Diseases and Health Promotion The potential of secondary prevention RR reduction 2-year event rate None % Aspirin25%6.0% B B25%4.5% Statin30%3.0% ACEI25%2.3%

World Health Organization Department of Chronic Diseases and Health Promotion Overall Percentage on Rx EUROASPIRE Survey Lancet 2001;357: Percentage Drugs

World Health Organization Department of Chronic Diseases and Health Promotion Overall Percentage in 10 countries Secondary Prevention of CHD WHO PREMISE 2003 Percentage Drugs

World Health Organization Department of Chronic Diseases and Health Promotion Prevention and Control of CVD Primary prevention Secondary prevention

World Health Organization Department of Chronic Diseases and Health Promotion Global Initiative For Treatment of major chronic diseases CHD/CeVD/RHD Bronchial asthma Diabetes Glaucoma Cancer (palliative care)

World Health Organization Department of Chronic Diseases and Health Promotion Objectives To improve Health outcomes Efficiency Equity

World Health Organization Department of Chronic Diseases and Health Promotion Is affordability a problem? Pakistan : statin 1 month supply = one third the monthly wage Kenya : Furosemide generic form is 2.5% that of the originator brand form

World Health Organization Department of Chronic Diseases and Health Promotion Kg of (rice/yam) that can be purchased with money required for buying the cheapest statin for 1 week Kg China 28 Egypt 34 Georgia 51 Indonesia5 Iran 1.4 Mozambique4.7 Nepal13 Pakistan24 Uruguay 35 China: 28 Kg of rice can be bought for cost of 1 week supply of statins

World Health Organization Department of Chronic Diseases and Health Promotion World Health Survey Diagnosed as angina (4%-14%) On Rx(14%-60%) Diagnosed angina –aspirin (1%-20%) Diagnosed angina –BB (<5%) (Bangladesh, Burkina Faso, China, India, Malawi, Malaysia, Mexico, Nepal, Sri Lanka, Vietnam)

World Health Organization Department of Chronic Diseases and Health Promotion Determinants of effective drug treatment Determinants of effective drug treatment AffordabilityAccessibility Quality and efficacy Appropriate use Evidence based prescription

World Health Organization Department of Chronic Diseases and Health Promotion Players and Processes Improve health outcomes by drug treatment AffordabilityAccessibility Quality and efficacy Appropriate use Evidence based prescription Manufacture Procurement Distribution Regulations Financing Public/private Reimbursement Insurance Research /development Incentives CME Doctors Referral links Patients/Families

World Health Organization Department of Chronic Diseases and Health Promotion How ? Assess situation Identify barriers Direct intervention Advocate for change

World Health Organization Department of Chronic Diseases and Health Promotion Price of Medicines Survey The survey will gather information on: Procurement / final prices Prices in different parts of the country Relative prices of proprietary / generic Affordability of treatment for ordinary people International difference in prices

World Health Organization Department of Chronic Diseases and Health Promotion Priority list of drugs Aspirin Thiazides Betablockers ACEI Statin Metformin Glibenclamide Insulin Salbutamol Beclometasone/oral steroids Aminophylline Benzathine penicillin Beta blocker eye drops Morphine (Model list / PHC / minimum monitoring/Safety )

World Health Organization Department of Chronic Diseases and Health Promotion Are there mechanisms to reduce drug prices ? Ensure generic medicines Seek volume discounts for group purchases Open competitive purchasing methods Monitor prices paid by other purchasers Eliminate duties and taxes and add-ons Partnership arrangements

World Health Organization Department of Chronic Diseases and Health Promotion Expected outcomes Reduce cost of drugs Improve accessibility Efficient procurement practices Evidence based prescriptions National programs addressing Rx needs through equitable programs Partnership arrangements with industry Enhance local production of generics

World Health Organization Department of Chronic Diseases and Health Promotion Affordability Accessibility Quality & efficacy Appropriate use prescription GIFT Global Initiative For Treatment of major chronic diseases